-
Mashup Score: 2
Uday R. Popat, MD, discusses the rationale behind evaluating itacitinib over other JAK inhibitors for graft-vs-host disease prophylaxis in a phase 2 study.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
Alexandra Gomez Arteaga, MD, discusses the rationale behind a retrospective study comparing Orca-T with posttransplant cyclophosphamide-based hematopoietic cell transplantation.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Alexandra Gomez Arteaga, MD, of @WeillCornell delves into a retrospective study comparing Orca-T with posttransplant cyclophosphamide-based hematopoietic cell transplantation. #BMSCT https://t.co/kuCEycWPds
-
-
Mashup Score: 3Long-Term Quality of Life Remains Positive for Transplant Patients, Regardless of Donor Match - 9 month(s) ago
Neel Bhatt, MD, discussed the importance of long-term patient monitoring following hematopoietic cell transplantation.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
The risk of long-term adverse events and QOL status remains an unknown for patients who undergo allo-HCT, especially those with nonmalignant conditions like aplastic anemia. A study conducted at @fredhutch sought to evaluate these outcomes. #BMSCT https://t.co/ffm0tRdvd0
-
-
Mashup Score: 0Exploring the Frailty Factor in Stem Cell Transplant Hospitalization - 10 month(s) ago
In an interview with Targeted Oncology, Kayla Giannetti, MSN, APRN-CNP, discussed the background of the study, along with its findings and implications for community oncologists.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Kayla Giannetti, MSN, APRN-CNP, discussed the background of the study, along with its findings and implications for community oncologists. #BMSCT | @ClevelandClinic https://t.co/QtENUmsUJu
-
-
Mashup Score: 1Role of Stem Cell Transplant in MDS - 1 year(s) ago
Dr Hana Safah discusses the role of stem cell transplant and reviews the eligibility criteria.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
WATCH: Hana Safah, MD, of @TulaneMedicine discusses the role of stem cell transplant and reviews the eligibility criteria. #BMSCT https://t.co/PyWFQ5EGkR
-
-
Mashup Score: 0
Though the benefit of consolidative stem cell transplant for patients who received A+CHP appeared less pronounced vs those treated with the CHOP regimen, the method is still supported for patients with CD30-positive peripheral T-cell lymphomas.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Consolidative stem cell transplant in patients with CD30-positive peripheral T-cell lymphomas who achieved complete response post-treatment with brentuximab vedotin and A+CHP showed improvements in PFS, OS, & more. #bmsct READ MORE: https://t.co/AIBmGKwM5M
-
-
Mashup Score: 1
Samer A. Srour, MD, MS, discusses some of the takeaways from the dose-expansion phase of an ongoing phase 1 trial evaluating Orca-Q.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Samer A. Srour, MD, MS, discusses some of the takeaways from the dose-expansion phase of an ongoing phase 1 trial evaluating Orca-Q. #Tandem23 #BMSCT | @MDAndersonNews @ASTCT https://t.co/k023cHtKB5
-
-
Mashup Score: 0
Melhem Solh, MD, discusses the future for patients with myelodysplastic syndrome and acute myeloid leukemia that harbors a TP53 gene mutation, and gives his own recommendations to community oncologists who are treating patients with this disease.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Melhem Solh, MD, recommends treating patients with myelodysplastic syndrome and acute myeloid leukemia that harbor a TP53 gene mutation. #BMSCT #MDS #AML | @NorthsideHosp https://t.co/5HXhuOJKWm
-
WATCH: Uday R. Popat, MD, discusses the rationale behind evaluating itacitinib over other JAK inhibitors for graft-vs-host disease prophylaxis in a phase 2 study. #BMSCT | @MDAndersonNews https://t.co/pya8gFkggX